5.72
+0.14(+2.51%)
Currency In USD
| Previous Close | 5.58 |
| Open | 5.62 |
| Day High | 5.81 |
| Day Low | 5.56 |
| 52-Week High | 7.82 |
| 52-Week Low | 2.77 |
| Volume | 1.41M |
| Average Volume | 738,979 |
| Market Cap | 220.72M |
| PE | -4.12 |
| EPS | -1.39 |
| Moving Average 50 Days | 5.51 |
| Moving Average 200 Days | 3.97 |
| Change | 0.14 |
If you invested $1000 in Protara Therapeutics, Inc. (TARA) 10 years ago, it would be worth $9.77 as of December 09, 2025 at a share price of $5.72. Whereas If you bought $1000 worth of Protara Therapeutics, Inc. (TARA) shares 5 years ago, it would be worth $260.59 as of December 09, 2025 at a share price of $5.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Protara Announces Closing of $75 Million Public Offering
GlobeNewswire Inc.
12 hours ago
NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the closing of its underw
Protara Announces Pricing of $75 Million Public Offering
GlobeNewswire Inc.
Dec 05, 2025 3:03 AM GMT
NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underw
Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients
GlobeNewswire Inc.
Dec 03, 2025 1:00 PM GMT
TARA-002 demonstrates 72% complete response rate at any time in BCG-Naïve patientsTARA-002 demonstrates a 69% complete response rate at the 6-month landmark and a 50% complete response rate at the 12-month landmark in BCG-Naïve patientsFavorable safe